Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time

Nature Communications

Volumn 8, Issue , 2017, Pages

  Lee, Bai Yu ^a   Clemens, Daniel L ^a   Silva, Aleidy ^b   Dillon, Barbara Jane ^a   Masleša Galic, Saša ^a   Nava, Susana ^a   Ding, Xianting ^c   Ho, Chih Ming ^b   Horwitz, Marcus A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Engineering IV   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP; DRUG; DRUG RESISTANCE; EXPERIMENTAL STUDY; IDENTIFICATION METHOD; OPTIMIZATION; TUBERCULOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; GERMFREE ANIMAL; HUMAN; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MICROBIOLOGY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MEDICATION ADHERENCE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; SPECIFIC PATHOGEN-FREE ORGANISMS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85011006728     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14183     Document Type: Article

References (50)

1. World Health Organization. Global Tuberculosis Report. Available at http://www.who.int/tb/publications/global-report/en/(2015).
2. Center for Disease Control. Treatment for TB Disease. Available at https://www.cdc.gov/tb/topic/treatment/tbdisease.htm (2016).
3. World Health Organization. Treatment of Tuberculosis: Guidelines 4th edn. Available at http://www.who.int/tb/publications/2010/9789241547833/en/(2010).
4. Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
5. Zumla, A. et al. Tuberculosis treatment and management-An update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Resp. Med. 3, 220-234 (2015).
6. Nuermberger, E. L., Spigelman, M. K. & Yew, W. W. Current development and future prospects in chemotherapy of tuberculosis. Respirology 15, 764-778 (2010).
7. Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: The need and the reality. Lancet 375, 2100-2109 (2010).
8. Silva, A. et al. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc. Natl Acad. Sci. USA 113, E2172-E2179 (2016).
9. Grosset, J. & Ji, B. in Mycobacteria: II. Chemother. 51-97 (Chapman and Hall, 1998).
10. Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit Care Med. 169, 421-426 (2004).
11. Li, S. Y. et al. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob. Agents Chemother. 59, 4026-4030 (2015).
12. Nuermberger, E. Using animal models to develop new treatments for tuberculosis. Semin Respir. Crit Care Med. 29, 542-551 (2008).
13. Wong, P. K. et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl Acad. Sci. 105, 5105-5110 (2008).
14. Al-Shyoukh, I. et al. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst. Biol. 5, 88 (2011).
15. Ding, X., Xu, H., Hopper, C., Yang, J. & Ho, C.-M. Use of fractional factorial designs in antiviral drug studies. Qual. Reliab. Eng. Int. 29, 299-304 (2013).
16. Jaynes, J., Ding, X., Xu, H., Wong, W. K. & Ho, C. M. Application of fractional factorial designs to study drug combinations. Stat. Med. 32, 307-318 (2013).
17. Ding, X. et al. Discovery of a low order drug-cell response surface for applications in personalized medicine. Phys. Biol. 11, 065003 (2014).
18. Wang, H. et al. Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9, 3332-3344 (2015).
19. Weiss, A. et al. A streamlined search technology for identification of synergistic drug combinations. Sci. Rep. 5, 14508 (2015).
20. Ding, X. et al. Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int. J. Nanomed. 7, 2281-2292 (2012).
21. Lefford, M. J. in The Mycobacteria: A Sourcebook (eds Kubica, G. P. & Wayne, L. G.) 947-977 (Dekker, 1984).
22. Williams, K. et al. Sterilizing activities of novel combinations lacking first-And second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 3114-3120 (2012).
23. Nuermberger, E. L. et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit Care Med. 170, 1131-1134 (2004).
24. Ahmad, Z. et al. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob. Agents Chemother. 55, 1527-1532 (2011).
25. Cynamon, M. H. & Sklaney, M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother. 47, 2442-2444 (2003).
26. Tyagi, S. et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc. Natl Acad. Sci. 112, 869-874 (2015).
27. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684-692 (2010).
28. Grosset, J. H. et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am. J. Respir. Crit. Care Med. 188, 608-612 (2013).
29. Diacon, A. H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am. J. Respir. Crit. Care Med. 191, 943-953 (2015).
30. Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLOS Med. 4, e344 (2007).
31. Saukkonen, J. J. et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit Care Med. 174, 935-952 (2006).
32. Denholm, J. T. et al. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: A prospective cohort study. Drug Healthcare Patient Saf. 6, 145-149 (2014).
33. Global Alliance for TB Drug Development. Handbook of anti-Tuberculosis agents. Tuberculosis (Edinb) 88, 85-86 (2008).
34. Fox, G. J. & Menzies, D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infectious Diseases Therapy 2, 123-144 (2013).
35. Swanson, R. V. et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 59, 3042-3051 (2015).
36. Bass, Jr J. B. et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am. J. Respir. Crit. Care Med. 149, 1359-1374 (1994).
37. Ahmad, Z. et al. Comparison of the Denver regimen against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65, 729-734 (2010).
38. Via, L. E. et al. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives. ACS Infect. Dis. 1, 203-214 (2015).
39. Williams, K. N. et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180, 371-376 (2009).
40. Pasipanodya, J. G. & Gumbo, T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob. Agents Chemother. 54, 2847-2854 (2010).
41. Irwin, S. M. et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob. Agents Chemother. 58, 4026-4034 (2014).
42. Lefford, M. J. in The Mycobacteria: A Sourcebook, Vol. 15 (eds Kubica, G.P. & Wayne, L.G.) 947-977 (Dekker, 1984).
43. Lu, Y. et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob. Agents Chemother. 55, 5185-5193 (2011).
44. Tasneen, R. et al. Sterilizing activity of novel TMC207-And PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 5485-5492 (2011).
45. Nuermberger, E. et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52, 1522-1524 (2008).
46. Tyagi, S. et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49, 2289-2293 (2005).
47. Mohd Abdul Rashid, M. B. et al. Identification and optimization of combinatorial glucose metabolism inhibitors in hepatocellular carcinomas. J. Lab Autom. 20, 423-437 (2015).
48. Weiss, A. et al. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18, 233-244 (2015).
49. Zarrinpar, A. et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci. Transl. Med. 8, 333ra349 (2016).
50. Glantz, S. & Slinker, B. Primer of Applied Regression and Analysis of Variance 2nd edn (McGraw-Hill, 2001).